AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Training Course РIN SILICO DRUG DISCOVERY & DESIGNING: INSIGHTS OF PROTEIN-LIGAND INTERACTIONS. Oct 01, 2016 at Le M̩ridien Bangalore Hotel in Bengaluru, India.

 CONFERENCE  Comments Off on Training Course – IN SILICO DRUG DISCOVERY & DESIGNING: INSIGHTS OF PROTEIN-LIGAND INTERACTIONS. Oct 01, 2016 at Le Méridien Bangalore Hotel in Bengaluru, India.
Aug 222016
 

 

Training Course – IN SILICO DRUG DISCOVERY & DESIGNING: INSIGHTS OF PROTEIN-LIGAND INTERACTIONS. Oct 01, 2016  at Le Méridien Bangalore Hotel in Bengaluru, India.

https://selectbiosciences.com/trainingCoursesID.aspx?tc=DDD16&pid=4820&conf=DDI16&se=india

http://selectbiosciences.com/conferences/index.aspx?conf=DDI16&se=india

http://selectbiosciences.com/conferences/venue.aspx?pid=4817&conf=DDI16&se=india

Dear Colleague,

SELECTBIO would like to remind you about its Training Course – IN SILICO DRUG DISCOVERY & DESIGNING: INSIGHTS OF PROTEIN-LIGAND INTERACTIONS. This is scheduled to be held on October 01, 2016 from 9:00am to 5:00pm at Le Méridien Bangalore Hotel in Bengaluru, India. This course will be held in conjunction with our 4th International Conference “Drug Discovery India 2016“. Attend the Training Course and the Conference andSave 10% against the regular registration charges.

PROFILE OF ATTENDEES
With basic knowledge in Life Science and Drug Design that would like to receive a comprehensive overview or refresher on the Drug Discovery Technology the target audience comprises:
• Student & Faculty: Bachelor, Masters, PhD, students as well as Faculty and Professors from Microbiology, Biochemistry, Biotechnology, Immunology, Pharmacy, Pharmaceutical Chemistry, Biomedical Technology, Genetics, Bioinformatics, Plant Science and Life Sciences.
• Professionals: Biotechnology, Bioinformatics and Pharmaceutical scientists from industry, academia and regulatory agencies.
Hands-on exercises will be performed individually using Software tools (no prior experience required).

COURSE CONTENTS
• Introduction of Drug Designing
• Science involved in Disease Target Identification
• Virtual Screening
Practical application will be done on 5 molecules and the software on which DEMONSTRATION & TRAINING will be given
• In-Silico Generation of Ligands by ChemSketch
• Conversion of mol files to pdf files by Open Babel
• Protein Optimization & Energy Minimization by SPDBV
• Molecular Docking by MGL Tools | Creation of Grid Parameter & Dock Parameter Files by AutoDock Software
• Running the Algorithm by Cygwin
• Selection of Potent Inhibitors on the basis of Binding Energies and Lipinski’s Rule of 5
• Structure Analysis – Protein & Ligand complex H-bond interaction by UCSF Chimera
• Prediction of Molecular Properties- Molinspiration
• Prediction of Bioactivity- Molinspiration & ACD iLabs
• Drug Likeness – Mol Soft
• Bioavailability & ADME- ACD iLabs
• Toxicity- OSIRIS Property Explorer & ACD iLabs

For more information, or to discuss registration options, please contact me on the details given below.

Thanks and Best Regards

Sakshi Modgil
Customer Services Manager
SELECTBIO INDIA
O: +91 172 5025050
M: +91 7696125050
s.modgil@selectbio.com

Copyright © 2016 SELECTBIO, All rights reserved.

 

///////////////Training Course,  IN SILICO DRUG DISCOVERY & DESIGNING, INSIGHTS OF PROTEIN-LIGAND INTERACTIONS, Oct 01, 2016  at Le Méridien Bangalore Hotel,  Bengaluru, India, selectbio

 

Share

Innogen summit India 2016, 18-19 Aug, Mumbai, India

 CONFERENCE  Comments Off on Innogen summit India 2016, 18-19 Aug, Mumbai, India
Aug 192016
 

 

i1Innogen summit India 2016, 18-19 Aug, Mumbai, India, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd………topic is Supergenerics, Innovation in Generics, commercialization, regulatory, other insights,

 

A0 a1

Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd, at Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — with DR ASHOK KUMAR OF IPCA at Holiday Inn-Mumbai Intl Airport.

 

A2

PANEL DISCUSSION, Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd , Dr. Nilima A. Kshirsagar, National Chair Clinical Pharmacology, ICMR Government of India, Yugal Sikri, Chairman – Pharmaceutical Management, School of Business Management, SVKM’s Narsee Monjee Institute of Management Studies — with Yugal Sikri,, Nilima A. Kshirsagarand ASHOK KUMAR OF IPCA at Holiday Inn-Mumbai Intl Airport.

ashit

Ashit sikka, Koji nakamura, Uttam kumar, allfdron TERUMO, AT Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — with Koji nakamura of terumo, Ashit Sikka and UTTAM KUMAR OF TERUMO at Holiday Inn-Mumbai Intl Airport.

 

INNO1 INNO3

ROHAN, RIDDHI AND PALLAVI OF INVENTICON

INNO4 S2

DR NIDHI SAPKAL OF ZIMLABS

S3

ALKA LUTHRA OF LUBRIZOL

 

SEEMA1

 

DR SEEMA SINGH, VP AND HEAD,-LEGAL AND IPM, MACLOEDS PHARMA, Innogen summit India 2016, 18-19 Aug, Mumbai, India,, HOTEL HOLIDAY INN, Mumbai International Airport,Organised by Inventicon Business Intelligence Pvt. Ltd — withSeema Singh.

 

lupin cadila

standing Mr Rajeev patil, Sr VP reg affairs Lupin and Mr Sushrut kulkarni Sr VP Zydus cadila, Head, Pharma tech cemtre — with sushrut kulkarni andrajeev patil.

Thanks to

STR1

Rohan Jagtap

Program Manager – Pharma & Lifesciences

 https://ci4.googleusercontent.com/proxy/XM6zLJNVF-KyjTdLe4_K-jsjBvWCfPVibLEfkfFi-qr6U362NxG0XVUkvsdpOUKmwJgUMkzmSETrv9F_bY4Pv0rEVxiUozAcfOcwUjawrQs2stF7iWDvdLcVkMJYElp6G8kNSGlsGwZJsFOoqQTnShF3BCHD=s0-d-e1-ft#https://docs.google.com/a/inventiconasia.com/uc?id=0BxGiCo9okSEbVlRmN0xxM1dpc1E&export=download

Inventicon Business Intelligence Pvt. Ltd.

Phone: +91 22 6511 3334 I Mob: +91 9011052025 Email: rohan.jagtap@inventiconasia.com

Times Square, Unit 1, Level 2, B Wing, Andheri Kurla Road, Andheri (E), Mumbai – 400059, MS – India.

http://inventiconasia.com/About-Us.aspxgards,

AGGENDA

////////

Share

Scaling up from mg to Kgs – Making your First GMP Batch

 companies, CONFERENCE  Comments Off on Scaling up from mg to Kgs – Making your First GMP Batch
Aug 032016
 

STR1

Scaling up from mg to Kgs – Making your First GMP Batch 

6th – 7th October 2016, Clearwater, USA

“the course was very informative and it allowed me to see the big picture from discovery stage to pilot plant” 
Genentech

Course Outline:

  • Introduction
  • Making the first 100g non-GMP Batch
  • Non-GMP vs GMP preparation
  • Physical version and form
  • Process safety and raw materials supply
  • Scaling into fixed vessels
  • Technology transfer
  • Genotoxic impurities
  • Case studies and Review

Who should attend:

  • Project managers
  • Project leaders
  • Bench chemists
  • New starters
  • MedChem Support teams

This course aims to provide attendees with a good understanding of the issues involved taking development candidates to the first in human trials.

Click here to Download the Course Brochure

Presented by Dr John Knight, JKonsult Ltd

John Knight

Managing Director at JKONSULT Ltd

STR1
Click here to Download the Course Brochure

“Brilliant Course, learn lots of tips and tricks”
Vertex
“First incursion into Chemical Development has been very, very educational. John’s way of explaining the material has been wonderful.”
Almirall

“Very clear and interesting sessions with a lot of relevant examples and not only theory.” 
Oribase Pharma
LINK
LITERATURE FROM INTERNET ON HIS TOPIC
//////////Scaling up,  mg to Kgs, Making,  First GMP Batch, SCIENTIFIC UPDATE,  JOHN KNIGHT, Clearwater, USA
Share

Virtue Insight invites you to the 9th Biosimilars Congregation 2016, 22nd Sept 2016, The Lalit Hotel, Mumbai, India

 CONFERENCE  Comments Off on Virtue Insight invites you to the 9th Biosimilars Congregation 2016, 22nd Sept 2016, The Lalit Hotel, Mumbai, India
Jul 132016
 

STR1

9th Biosimilars Congregation 2016 during 22nd September 2016 Mumbai,  INDIA

22nd September 2016, The Lalit Hotel, Mumbai, India

Link http://www.virtueinsight.com/pharma/9th-Biosimilars-Congregation-2016/

ANINDITA DAS

ANINDITA DAS

Dr. Reddy’s Laboratories

MANISH VERMA

MANISH VERMA

Sanofi

DEBOLINA PARTAP

DEBOLINA PARTAP

Wockhardt

PARIKSHIT CHAUDHARI

PARIKSHIT CHAUDHARI

Nestle

HANMANT BARKATE

HANMANT BARKATE

Intas Pharmaceuticals

CONFERENCE INTRODUCTION:-

Virtue Insight invites you to the 9th Biosimilars Congregation 2016 during 22nd September 2016 Mumbai – India. This 9th Biosimilars Congregation 2016 brings together scientists, researchers and CROs from around the world. Biologics are a highly effective class of medicines that are based on naturally occurring proteins and produced using living cells. Current concepts of drugs and biologics, Unique considerations for biologics, Early clinical development essentials, Cancer therapeutics, Comparability for Biologics, Biosimilar approvals are the points of discussion in this session.

9th Biosimilars Congregation 2016 conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Hence, this global event will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscapes, biosimilar guidelines to the legal and economic aspects and current challenges in biosimilar development. This biosimilar conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place. By attending this biologics conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for biosimilars stakeholders to discuss and share best practices in expediting development in Biosimilars 2016 and onwards.

 

KEY THEMES DISCUSSED IN THIS CONFERENCE:-

  • Global biopharma policy & market trends
  • The future of biosimilars in India
  • The evolving biosimilar sector: Trends and Implications
  • Complex biological models in biosimilar development
  • Viable extrapolation strategies for biosimilars with special emphasis on TNF antagonists
  • Effectively communicate the value of biosimilar products to raise confidence in the class
  • Improving characterization of biosimilars with technology
  • Create a robust patient services and reimbursement support program for biosimilar products
  • The future of the biosimilar industry – mapping the evolution and development of the biosimilar sector
  • Forecasting the financial growth of biosimilars in the global healthcare marketplace
  • Planning of a biosimilar development project – what to consider from the very beginning
  • Clinical development strategies for biosimilars
  • Gaining Better Market Access: Is Commercial CMO Acceptable for the Biosimilars Market?
  • Regulatory Updates and Development
  • Be part of a major networking opportunity

 

WHO WILL YOU MEET:-

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

  • Biopharmaceuticals/ Biotherapeutics
  • Follow on Biologics/Follow on Proteins
  • Biologics/Biotechnology/ Biogenerics
  • Legal Affairs
  • Intellectual Property
  • Health Economics
  • Pricing and Reimbursement
  • Clinical Immunology
  • Principal Scientist
  • Chief Scientific Officer
  • Process Control and Analytical Technologies
  • Analytical Characterisation
  • Regulatory Compliance
  • Pharmacovigilance
  • Drug Safety & Risk Management
  • Quality Affairs/ Quality Control
  • New Product Development
  • Process Science
  • Portfolio Management
  • Research & Development
  • Business Development
  • Business Operations
  • Scientific Affairs
  • Commercial Affairs

 

WHY SHOULD YOU ATTEND?

Get more from the event, with a broader scope bringing the whole communications value chain together? Enjoy and make the best out of ourdedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margin

Fen Castro

Fen Castro

Head – Productions

Virtue Insight

Tel (India) –       + 91 44 64614333

Mobile (India) –  + 91 9003 26 0693

Tel (UK) –          + 44 2036120886

Fen Castro fen@virtuefirms.com
Cc: Siddhaarth siddhaarth@virtueinsight.co.in

Link http://www.virtueinsight.com/pharma/9th-Biosimilars-Congregation-2016/

 

//////

Share
 Newer Entries
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: